आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

santen oy* - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml+5 mg/ml

आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - dorzolamidum hýdróklóríð - augndropar, lausn - 20 mg/ml

यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - sykursýki, tegund 2 - lyf notuð við sykursýki - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , þrefaldur samsetning meðferð) sem viðbót til að fæði og æfing í sjúklingar ekki nægilega stjórn á eigin hámarks þolað skammt af sjúklingar og sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20mg/ml+5 mg/ml

आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf - ibandronate sodium monohydrate - filmuhúðuð tafla - 150 mg

यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

mylan pharmaceuticals limited - zoledronsýra - brot, bein - lyf til að meðhöndla beinsjúkdóma - fyrirbyggja beinagrind atburðum tengdum (sjúkleg beinbrot, hrygg þjöppun, geislun eða skurðaðgerð á að beinum, eða æxli völdum álíka) í fullorðinn sjúklinga með langt illkynja þar bein;meðferð fullorðinn sjúklinga með æxli völdum álíka (tih).

यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

teva b.v. - zoledronsýra - fractures, bone; cancer - lyf til að meðhöndla beinsjúkdóma - forvarnir á beinagrindatengdum viðburðum og meðferð við blóðkalsíumhækkun vegna æxla.

यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - sykursýki, tegund 2 - lyf notuð við sykursýki - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , þrefaldur samsetning meðferð) sem viðbót til að fæði og æfing í sjúklingar ekki nægilega stjórn á eigin hámarks þolað skammt af sjúklingar og sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - polymyxinum b súlfat; oxytetracyclinum hýdróklóríð; hydrocortisonum acetat - eyrna-/augndropar, dreifa

यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - ibandrónsýra - beinþynning, eftir tíðahvörf - lyf til að meðhöndla beinsjúkdóma - meðferð beinbrot í tíðahvörf konur á jókst hættan á beinbrot (sjá kafla 5. lækkun í hættu á hryggbrot hefur verið sýnt fram á, virkni á lærlegg háls beinbrot hefur ekki verið staðfest.